726136-49-8

Basic information

• Product Name: 1-(8-BroMo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone
• Synonyms: 1-(8-BroMo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone
• CAS NO: 726136-49-8
• Molecular Formula: C₁₁H₉BrF₃NO
• Molecular Weight: 308.0944696
• Mol File: 726136-49-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(8-BroMo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(8-BroMo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone(726136-49-8)
• EPA Substance Registry System: 1-(8-BroMo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone(726136-49-8)

Safety Data

• Hazardous Substances Data: 726136-49-8(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry Research:
1-(8-BroMo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone is used as a research compound for its potential pharmacological activities. Its unique chemical structure allows for the exploration of various biological interactions and therapeutic applications.
Used in Drug Development:
In the pharmaceutical industry, 1-(8-BroMo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethanone is used as a starting material or intermediate in the synthesis of new drugs. Its chemical properties make it a valuable component in the development of novel therapeutic agents.

Upstream product

• 50-00-0 formaldehyd 
• 215797-81-2 N-(3-bromophenethyl)-2,2,2-trifluoroacetamide 
• 64-19-7 acetic acid 

Downstream Products

• 726136-51-2 1,2,3,4-tetrahydro-8-[2-(trifluoromethyl)phenyl]isoquinoline 
• 726136-50-1 1,2,3,4-tetrahydro-6-[2-(trifluoromethyl)phenyl]isoquinoline 
• 226942-29-6 6-bromo-1,2,3,4-tetrahydroisoquinoline 
• 75416-51-2 8-bromo-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

HISTAMINE H3 INVERSE AGONISTS AND ANTAGONISTS AND METHODS OF USE THEREOF

Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF

This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.

HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF

The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.

Certain pyrazoline derivatives with kinase inhibitory activity

The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.

S1P RECEPTOR MODULATING COMPOUNDS AND USE THEREOF

The present invention relates to compounds of the general formula (I) that have activity as SlP receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate SlP receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behcet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

NOVEL COMPOUNDS

The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the ph

NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS

The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the ph

CB 1/CB 2 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN

Compounds of formula (I) or pharmaceutically acceptable salts thereof wherein Ar?1?, Ar?2?, R?1?, R?2?, n and X are as defined in the specificationas well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in th